eClinical Technology and Industy News

CareDx Partners with the European Society for Organ Transplantation to Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the European Society for Organ Transplantation (ESOT) to provide education for its membership on the clinical evidence supporting the use of donor-derived cell-free DNA (dd-cfDNA) to monitor transplanted organ health.

“CareDx’s partnership with the European Society for Organ Transplantation represents a key step forward in educating the European transplant community about the clinical utility of AlloSeq cfDNA, our kit version to allow donor-derived cell-free DNA assessment,” said Reg Seeto, CEO and President of CareDx. “AlloSeq provides clinical information about allograft injury and the risk of rejection. We look forward to working with ESOT in expanding access to this leading technology, and over time making it the standard of care for organ transplant patients globally.” 

“We are excited to partner with CareDx, to disseminate the knowledge about non-invasive technologies for the surveillance of graft health and rejection.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives